Paper Details

  1. Home
  2. Paper Details

Comparison of diflunisal and piroxicam in the management of patients with rheumatoid arthritis.

Author: RiceD M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Diflunisal and piroxicam were equally effective and well-tolerated in treating active rheumatoid arthritis over a 12-week period. Both medications significantly improved joint swelling, pain, and patient-reported disease severity.
Paper Details　
Original Abstract of the Article :
The efficacy and tolerability of diflunisal (500 mg orally, twice daily) and piroxicam (20 mg orally, once daily) were compared in a 12-week open-label study in 44 patients with active rheumatoid arthritis. Both medications were equally effective and generally well tolerated. No significant differen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3329968

データ提供：米国国立医学図書館（NLM）

Diflunisal and Piroxicam: A Tale of Two Oases in the Desert of Rheumatoid Arthritis

The desert of rheumatoid arthritis (RA) can be a painful and debilitating landscape, often leaving individuals with limited mobility and a diminished quality of life. This research investigates the efficacy and tolerability of two nonsteroidal anti-inflammatory drugs (NSAIDs), diflunisal and piroxicam, in managing active RA. The study involved 44 participants with RA, comparing the effects of diflunisal (500 mg twice daily) and piroxicam (20 mg once daily) over a 12-week period. The findings revealed that both medications were equally effective in reducing RA symptoms, including joint swelling, tenderness, and pain. Both medications were also generally well tolerated, with minimal adverse effects.

Two Paths in the Desert of Rheumatoid Arthritis

The research suggests that both diflunisal and piroxicam can be effective options for managing RA, offering patients a choice based on individual needs and preferences. The finding that both medications were equally effective and well tolerated is encouraging, providing healthcare professionals with more flexibility in treating RA. The study highlights the importance of carefully considering patient-specific factors when choosing the best NSAID for managing RA.

Navigating the Desert of Rheumatoid Arthritis with NSAIDs

This research provides valuable insights into the use of NSAIDs for managing RA. It underscores the importance of consulting with a healthcare professional to determine the best treatment plan for your individual needs. Remember, like a traveler navigating a desert landscape, finding the right approach to RA management is essential for maintaining a comfortable and fulfilling life.

Dr.Camel's Conclusion

This research reminds us that the desert of rheumatoid arthritis can be navigated with a variety of treatment options. It's a reminder that like a wise desert guide, we should seek out multiple perspectives and choices when it comes to managing our health.

Date :
  1. Date Completed 1988-07-12
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

3329968

DOI: Digital Object Identifier

3329968

Related Literature

Article Analysis
・Side Effects of diflunisal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.